Liquidia Corporation · NASDAQ:LQDA

Liquidia — Q3 2026 Earnings Presentation

10 slides from Liquidia's earnings presentation, Nov 10, 2026

  1. Slide 1: Third Quarter 2026 Earnings & Corporate Update

    Third Quarter 2026 Earnings & Corporate Update Liquidia Corporation November 10, 2026 ©2026 LIQUIDIA CORPORATION ALL RIGHTS RESERVED

  2. Slide 2: Forward-looking statements

    Forward-looking statements This presentation may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation other than statements of historical facts, including statements regarding our future results o

  3. Slide 3: Use of Non-GAAP Financial Information

    Use of Non-GAAP Financial Information To supplement our financial results presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), this presentation includes certain non-GAAP financial measures, such as Adjusted EBITDA. We believe the use of such non-GAAP financial measures

  4. Slide 4: Third quarter 2026 highlights

    Third quarter 2026 highlights CONTINUED GROWTH IN EXPANDING CLINICAL OPERATING WITH CATEGORY PIPELINE LEVERAGE $222.7M net product sales 11 studies $140.5M adj. EBITDA* 5th consecutive quarter of On-going, recruiting or planned 5th consecutive quarterly growth in referrals and revenue clinical studi

  5. Slide 5: Continued strong demand for YUTREPIA from PAH prescribers

    Continued strong demand for YUTREPIA from PAH prescribers More first-time prescribers in October 2026 than in September 2026 BREADTH % YUTREPIA prescribers have written ~77% for at least one PAH patient 1,300 1+ referral Prescribers ~60% % daily referral rate in October as referred 2+ 2+ referrals >

  6. Slide 6: Clinical studies on-going, recruiting, or initiating within the next year

    Clinical studies on-going, recruiting, or initiating within the next year Program Phase II Phase III Phase IV Diseases Name Objective Status LIQ861 NCT07759804 PAH LTI-403 Safety and feasibility of transitioning from oral selexipag to YUTREPIA Recruiting treprostinil dry powder 3-5x daily, DPI PAH S

  7. Slide 7: Strong product pull-through and operating leverage

    Strong product pull-through and operating leverage Q3’26 included $212.2 million in paid patient demand sales Net Product Sales +31% Adjusted EBITDA* +46% Q3/Q2 Q3/Q2 $222.7 $140.5 $170.4 $ millions (M) $ millions (M) $96.3 $129.9 $71.2 $90.1 $51.7 $27.3 $10.1 Q3 Q4 Q1 Q2 Q3 Q3 Q4 Q1 Q2 Q3 2025 2025

  8. Slide 8: Q&A session

    Q&A session Dr. Roger Jeffs Scott Moomaw Chief Executive Officer Chief Commercial Officer Michael Kaseta Dr. Rajeev Saggar COO & CFO Chief Medical Officer Russell Schundler General Counsel ©2026 LIQUIDIA CORPORATION ALL RIGHTS RESERVED 8

  9. Slide 9: Key financial metrics

    Key financial metrics Select Consolidated Statements of Operations Data Three Months Ended in thousands 9/30/26 9/30/25 Product sales, net $222,744 $51,669 Service revenue, net 2,556 2,673 Total Revenue 225,300 54,342 Cost of product sales 13,985 2,295 Cost of service revenue 792 878 R&D 25,269 9,34

  10. Slide 10: Reconciliation of Net Income (Loss) to Adjusted EBITDA

    Reconciliation of Net Income (Loss) to Adjusted EBITDA Three months ended (unaudited, in thousands) Sept 30, 2026 June 30, 2026 Mar 31, 2026 Dec 31, 2025 Sept 30, 2025 Net income (loss) $(236,328) $74,722 $52,862 $14,555 $(3,533) Interest expense, net 2,880 3,820 4,722 5,232 5,300 Income tax expense

Liquidia — Q3 2026 Earnings Presentation on 6ix